The Latest Cardiac and Vascular News
SANTA CLARA, Calif.–(BUSINESS WIRE)–VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 millio
The new capital will advance the SERRA-I early feasibility study, engineering development, and preparation for additional studies on coronary microvascular dysfunction. SANTA CLARA, Calif.–(BUSINESS WIRE)–VahatiCor, a medtech company transforming cardiac care for Coronary Microvascular Dysfunction (CMD), today announced the successful closing of its $23 million Series B financing led by S3 […]
Demonstrated a Reduction of Symptoms with Short Procedural and Recovery Times Leading Coronary Physiology Experts Appointed Co-Principal Investigators for Planned U.S. Early Feasibility Study SANTA CLARA, Calif., Oct. 28, 2024 /PRNewswire/ — VahatiCor, a leader in cardiovascular…
